These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 30342298)

  • 1. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM
    Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study.
    Komiya I; Yamamoto A; Sunakawa S; Wakugami T
    Lipids Health Dis; 2021 Feb; 20(1):17. PubMed ID: 33610176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
    Nicholls SJ; Lincoff AM; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Pedersen TR; Ridker PM; Ray K; Karlson BW; Lundström T; Wolski K; Nissen SE
    Clin Cardiol; 2018 Oct; 41(10):1281-1288. PubMed ID: 30125052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
    Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM;
    Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
    Yokote K; Yamashita S; Arai H; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S
    Cardiovasc Diabetol; 2021 May; 20(1):96. PubMed ID: 33947390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.
    Yamashita S; Masuda D; Matsuzawa Y
    Curr Atheroscler Rep; 2020 Jan; 22(1):5. PubMed ID: 31974794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
    Fruchart JC; Hermans MP; Fruchart-Najib J
    Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy.
    Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK
    Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial.
    Doi T; Langsted A; Nordestgaard BG
    Atherosclerosis; 2024 Jun; 393():117556. PubMed ID: 38678642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial.
    Yamashita S; Hirano T; Shimano H; Tsukamoto K; Yoshida M; Yoshida H
    Eur J Clin Invest; 2024 Sep; 54(9):e14227. PubMed ID: 38662591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
    Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
    Diabetes Care; 2018 Mar; 41(3):538-546. PubMed ID: 29298800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report.
    Iitake C; Masuda D; Koseki M; Yamashita S
    Cardiovasc Diabetol; 2020 Nov; 19(1):201. PubMed ID: 33246467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] Trial).
    Nelson AJ; Navar AM; Mulder H; Wojdyla D; Philip S; Granowitz C; Peterson ED; Pagidipati NJ
    Am J Cardiol; 2020 Oct; 132():36-43. PubMed ID: 32773223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.